Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial - Summary - MDSpire
Advertisement
Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial
To assess the efficacy and safety of MuShengshu (MSS) combined with foundational therapies, including specific treatments like desonide and triamcinolone, in patients with mild-to-moderate atopic dermatitis (AD).
Key Findings:
MuShengshu is a weakly acidic bath solution with potential benefits for AD, particularly in restoring skin barrier function.
The study aims to provide high-quality evidence regarding MSS's efficacy and safety in a clinical setting.
Ethical approval and registration have been completed, with participant recruitment ongoing and expected to conclude by June 2026.
Interpretation:
The trial is expected to provide evidence for incorporating traditional Chinese herbal bath solutions into AD management, particularly addressing the limitations of current treatments such as side effects and insufficient efficacy.
Limitations:
The study is limited to a single center, which may affect generalizability and introduce potential biases.
Results will only be available after data analysis in August 2026, necessitating further research to confirm findings.
Conclusion:
The findings may support the use of MSS as an adjunctive treatment for mild-to-moderate AD, potentially improving patient outcomes, but further research will be essential to validate these results.
